Skip to the main content.

Breast Cancer

EVERA

About the EVERA Trial



Table of Contents

Major Presentations and Milestones

evERA Trial design, results, and conclusions

evERA Sentiments and Criticisms

evERA Temporal Sentiment Arc

Professional Resources : Interactive Tweet History, Influence Diagram, Sentiment Table, AI Chatbot

evERA Trial: Major Presentations and Milestones

Primary speakers driving the story

At ESMO 2025, Erica Mayer, MD (Dana-Farber Cancer Institute) presented the phase 3 evERA program evaluating an oral SERD strategy combined with everolimus after prior CDK4/6 inhibitor therapy in HR+/HER2− metastatic breast cancer. KOL discussion quickly centered on the biomarker-defined nature of benefit—particularly the magnitude of effect in ESR1-mutant disease—and on whether the regimen meaningfully improves outcomes for ESR1 wild-type tumors.

In parallel, clinician commentary highlighted how the evERA dataset was being incorporated into broader “2025” treatment algorithms for HR+/HER2− metastatic disease, often alongside other post-CDK4/6 endocrine-combination strategies.

At SABCS 2025, Hope S. Rugo, MD (UCSF Helen Diller Family Comprehensive Cancer Center) presented additional evERA subgroup/biomarker-focused analyses. Several posts emphasized consistency of benefit across genomic and clinical subgroups, including PI3K-pathway alterations, and reinforced the clinical framing of evERA as part of an emerging “combo endocrine” post-CDK4/6 landscape.

evERA Trial Design, Results, and Conclusions

Trial Design:

Based on the tweet dataset, evERA is a phase 3 trial in HR+/HER2− metastatic breast cancer after prior CDK4/6 inhibitor therapy, comparing giredestrant (oral ER antagonist + degrader) + everolimus versus standard endocrine therapy (ET) + everolimus. Discussion repeatedly separated outcomes for ESR1-mutant versus ESR1 wild-type tumors, suggesting biomarker-stratified interpretation is central to clinical use.

Primary Results (as discussed on X):

Multiple KOLs described a large PFS benefit in ESR1-mutant disease. Dr Sarah Sammons summarized: “Giredestrant + everolimus doubled PFS vs SOC ET + everolimus post-CDK4/6 in HR+/HER2– MBC ESR1 mut population; 10 mo vs 5.4 mo in ESR1-mut tumors.”

Oncology Brothers reported a similar quantitative signal for the ESR1-mutant subgroup: “mPFS ~10mos vs 5.5mos (HR: 0.38) in ESR1m pts” and noted “OS immature (HR: 0.62).”

Subgroup / biomarker signals highlighted at SABCS 2025:

Gaia Griguolo, MD described a subgroup analysis presented by @hoperugo at SABCS 2025: “Benefit of giredestrant+everolimus Vs ET+everolimus Is observed regardless of: -PIK3CA/AKT1/PTEN alterations -Duration of prior CDK4/6.”

Safety / tolerability (as discussed on X):

In the available tweets, Dr Rugo stated “no added toxicity” in her ESMO 2025 post, framing the combination as clinically usable if efficacy is confirmed in the intended biomarker-defined population.

Key Conclusions (from the tweet discourse):

Across ESMO 2025 and SABCS 2025 posts, evERA is characterized as a post-CDK4/6 endocrine-combination strategy with a substantial PFS signal in ESR1-mutant tumors. The dominant implementation question raised by KOLs is whether the benefit extends meaningfully beyond ESR1-mutant disease, and how to position this regimen among other emerging SERD-based combinations.

evERA Sentiments and Criticisms

Positive Reception:

Hope Rugo, MD (#ESMO25): “marked improvement in PFS and ORR in mESR1 and ITT… no added toxicity. Great new and effective Rx combination.” https://x.com/hoperugo/status/1979478467725902087

Dr Sarah Sammons (#ESMO25) emphasized the magnitude of the ESR1-mutant effect size: “10 mo vs 5.4 mo in ESR1-mut tumors.” https://x.com/drsarahsam/status/1979466087772074106

At SABCS 2025, Hope Rugo, MD positioned evERA as part of a broader pattern of benefit for SERD strategies across ESR1-mutant disease: “EVERA also shows benefit with giredestrant/EVE across mESR1 as did EMBER3.” https://x.com/hoperugo/status/1999204082469224503

Critical Perspectives / Cautions:

Erika Hamilton, MD, FASCO underscored biomarker restriction and cautioned against “all-comers” interpretation: “No benefit among those patients WITHOUT ESR1m… ⚠️ benefit is NOT in all-comers!!! ⚠️” https://x.com/ErikaHamilton9/status/1979469238508175470

Similarly, Dr Sarah Sammons noted: “No major benefit in ESR1-WT sub-analysis.” https://x.com/drsarahsam/status/1979466087772074106

Collectively, the critique is not about whether the ESR1-mutant subgroup benefits (broad agreement that it does), but about generalizability (ESR1 wild-type), and the degree to which clinicians should treat evERA as a biomarker-driven regimen rather than a universal post-CDK4/6 option.

evERA Temporal Sentiment Arc

2025 (ESMO 2025: Initial high-visibility efficacy interpretation)

Primary/KOL tweets:

2025 (SABCS 2025: Biomarker refinement and subgroup generalizability)

Primary/KOL tweets:

Across the 2025 cycle, the community’s discussion progressed from an ESMO “signal reveal” (large ESR1-mutant PFS effect, favorable tolerability framing) to a SABCS “refinement phase” emphasizing subgroup consistency and clinical positioning in an increasingly crowded post-CDK4/6 endocrine-combination landscape.

evERA Professional Resources